Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2019 06:30 ET | Source: Veru Inc.

Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

-- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU),...
August 28, 2019 08:30 ET | Source: Veru Inc.

Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
August 27, 2019 08:30 ET | Source: Veru Inc.

Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
August 08, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter

Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen...
August 01, 2019 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th

MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
July 18, 2019 14:07 ET | Source: Veru Inc.

Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment

MIAMI, July 18, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
June 26, 2019 08:30 ET | Source: Veru Inc.

Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia

--Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway—-- TADFIN is a First Novel Combination Formulation of Tadalafil and...
June 04, 2019 08:00 ET | Source: Veru Inc.

Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA

— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market...
May 28, 2019 08:30 ET | Source: Veru Inc.

Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th

MIAMI, May 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
May 15, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results

-- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising –-- Strong Financial Results for Q2 and YTD FY 2019 ---- Company to Host Investor Conference Call on...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right